ITGB3

Across TCGA pan-cancer cohorts, ITGB3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ITGB3 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ITGB3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ITGB3 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where ITGB3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.366	0.880	.003	41	view →
PDAC	DFS	Quartile	II,III,IV	0.302	0.665	.008	33	view →
LUAD	DFS	Tertile	III,IV	0.238	0.916	<.001	32	view →
LSCC	DFS	Tertile	III,IV	0.446	1.000	.019	8	view →
GBM	OS	Median	All	0.423	0.660	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ITGB3–CCRCC (DFS)

Open the CCRCC breakdown →